Chimeric Antigen Receptor T-cell Therapies for Hematological Malignancies

CCR Grand Rounds James Kochenderfer, M.D., is a tenure-track investigator in the Experimental Transplantation and Immunology Branch (ETIB) of the National Cancer Institute (NCI). For the past 12 years, Dr. Kochenderfer has focused on a full range of chimeric antigen receptor (CAR) research from designing and cons tructing new CARs to conducting clinical trials. Dr. Kochenderfer designed and constructed a novel anti-CD19 CAR and then participated in a clinical trial of this CAR. This clinical trial was the first to demonstrate antigen-specific activity of anti-CD19 CARs in humans. This work in anti-CD19 CAR T cells led to the first Food and Drug Administration-approved CAR T-cell therapy for lymphoma. Dr. Kochenderfer designed the first chimeric antigen receptor targeting B-cell maturation antigen (BCMA). He then led the first clinical trial of T cells expressing an anti-BCMA CAR as a treatment for mul tiple myeloma. Dr. Kochenderfer is currently principle investigator of CAR T-cell clinical trials targeting lymphoma, leukemia, and multiple myeloma. He also leads a lab that designs new CARs and studies CAR T-cell biology. Dr. Kochenderfer received his M.D. from West Virginia University and then co mpleted training in internal medicine at Vanderbilt University, a medical oncology fellowship at the M.D. Anderson Cancer Center, and a hematology fellowship at Baylor College of Medicine, followed by postdoctoral research training in T-cell immunotherapy at the National Cancer Ins...
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video

Related Links:

Brian Walker, Ph.D., with the Myeloma Center at the University of Arkansas for Medical Sciences has received a $542,486, three-year grant from the Leukemia &Lymphoma Society to look at changes in the DNA sequence that affects the development and advancement of multiple myeloma.
Source: Arkansas Business - Health Care - Category: American Health Source Type: news
Publication date: Available online 7 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Deepu Madduri, Madhav V. Dhodapkar, Sagar Lonial, Sundar Jagannath, Hearn Jay ChoAbstractTherapeutic monoclonal antibodies targeting SLAMF7 and CD38 are the first classes of targeted immune therapies approved for multiple myeloma, a cancer of plasma cells. These agents are effective, particularly in combination with immunomodulatory drugs lenalidomide and pomalidomide. The next generation of myeloma immunotherapy under investigation consists of T cell-directed strategies designed to promote cytotoxic activity against my...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Therapeutic monoclonal antibodies targeting SLAMF7 and CD38 are the first classes of targeted immunotherapies approved for multiple myeloma, a cancer of plasma cells. These agents are effective, particularly in combination with the immunomodulatory drugs lenalidomide and pomalidomide. The next generation of myeloma immunotherapy under investigation consists of T-cell –directed strategies designed to promote cytotoxic activity against myeloma cells, as embodied by chimeric antigen receptor–modified T cells (CAR-T) and bispecific T-cell–engaging agents.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Source Type: research
The objective is, therefore, to examine the relation between co-morbid CVD at cancer diagnosis and HRQoL among cancer survivors diagnosed with colorectal, thyroid, prostate, endometrium, ovarian cancer, melanoma, (non-)Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), or multiple myeloma (MM) in an exploratory population-based cross-sectional study. Material and methods: Analyses were performed on combined data sets from the PROFILES and Netherlands Cancer Registry (NCR). Data on co-morbid CVD at cancer diagnosis was extracted from the NCR. HRQoL was measured via PROFILES at a median of 4.6 years after cancer di...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Therapeutic monoclonal antibodies targeting SLAMF7 and CD38 are the first classes of targeted immune therapies approved for multiple myeloma, a cancer of plasma cells. These agents are effective, particularly in combination with immunomodulatory drugs lenalidomide and pomalidomide. The next generation of myeloma immunotherapy under investigation consists of T cell-directed strategies designed to promote cytotoxic activity against myeloma cells, as embodied by chimeric antigen receptor-modified T (CAR-T) cells and bi-specific T cell engaging agents.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
ConclusionThe use of a pediatric-inspired protocol for high-risk AYA ALL patients was effective and well tolerated with improvement in OS and DFS compared with historical data using adult protocols in such populations.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This article introduces the main concepts and addresses the most relevant clinical modalities of cellular immunotherapies for hematological malignancies: antigen non-specific T cell therapy, genetically modified T cell receptor (TCR) T cell therapy, chimeric antigen receptor (CAR) T cell therapy, and CAR-T cell clinical trials in leukemia, lymphoma, and multiple myeloma. Clinical trials have shown encouraging results, but future studies may need to incorporate novel CAR constructs or targets with enhanced safety and efficacy to ensure long-term benefits. PMID: 31338822 [PubMed - in process]
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
This study aimed to evaluate whether gait speed and grip strength predicted clinical outcomes among older adults with blood cancers. We prospectively recruited 448 patients aged 75 years and older presenting for initial consultation at the myelodysplastic syndrome/leukemia, myeloma, or lymphoma clinic of a large tertiary hospital, who agreed to assessment of gait and grip. A subset of 314 patients followed for ≥6 months at local institutions was evaluated for unplanned hospital or emergency department (ED) use. We used Cox proportional hazard models calculated hazard ratios (HRs) and 95% confidence intervals (CIs) for s...
Source: Blood - Category: Hematology Authors: Tags: Free Research Articles, Myeloid Neoplasia, Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research
Conditions:   Adenocarcinoma;   Adenocystic Carcinoma;   Anal Cancer;   Appendix Cancer;   Brain Tumor;   Glioblastoma;   Astrocytoma;   Bile Duct Cancer;   Cholangiocarcinoma;   Bladder Cancer;   Bone Cancer;   Synovial Sarcoma;   Chondrosarcoma;   Liposarcoma;   Sarcoma, Kaposi;   S arcoma,Soft Tissue;   Sarcoma;   Osteosarcoma;   CNS Cancer;   Brain Stem Neoplasms;   Breast Cancer;   Cervical Cancer;   Colorectal Cancer; &n...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The objective of this study was to develop a population-pharmacokinetic model of durvalumab in patients with various hematologic malignancies and to investigate the effects of demographic and disease factors on the pharmacokinetics in this population.MethodsA total of 1812 concentrations from 267 patients with myelodysplastic syndromes, acute myeloid leukemia, multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma were included in the analysis.ResultsThe pharmacokinetics of durvalumab was adequately described by a two-compartment model with first-order elimination. A decrease in durvalumab clearance over time was main...
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
More News: Allergy & Immunology | Baylor College of Medicine | Biology | Cancer | Cancer & Oncology | Clinical Trials | Cytology | Food and Drug Administration (FDA) | General Medicine | Hematology | Immunotherapy | Internal Medicine | Leukemia | Lymphoma | Myeloma | Study | Training | Transplants | Universities & Medical Training